Effect of KW-8232, a Novel Anti-osteoporotic Agent, on Bone Loss in Sciatic Neurectomized Rats.

DOI Web Site Web Site Web Site Web Site ほか1件をすべて表示 一部だけ表示 参考文献20件
  • Uchii Masako
    General Pharmacology, Drug Discovery Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd.
  • Takashima Miyuki
    General Pharmacology, Drug Discovery Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd.
  • Sugiyama Tomomi
    General Pharmacology, Drug Discovery Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd.
  • Kosaka Nobuo
    General Pharmacology, Drug Discovery Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd.

書誌事項

タイトル別名
  • Effect of KW-8232 a Novel Anti-osteopor

この論文をさがす

抄録

The purpose of this study was to evaluate the effects of 3-[bis(4-hydrozuphenyl)methyl]-2-[4-(2-chlorophenyl)-piperazin-1-ylcarbonyl]-1-(2-dimethylaminoethyl) indole methanesulfonate (KW-8232), a novel anti-osteoporotic agent, on bone loss in neurectomized rats. We also investigated the effect of KW-8232 on bone resorption in this animal model. Male Sprague-Dawley rats underwent unilateral hind-limb immobilization by sciatic neurectomy. KW-8232 (3, 10 and 30 mg/kg, p.o.) was effective in inhibiting femoral bone loss. KW-8232 decreased urinary pyridinoline and deoxypyridinoline excretion. These results indicate that KW-8232 effectively prevents the bone loss due to immobilization.

収録刊行物

  • Jpn.J.Pharmacol.

    Jpn.J.Pharmacol. 78 (2), 241-243, 1998

    公益社団法人 日本薬理学会

参考文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ